Nonclinical precedent Request an invite

Lyfgenia: which tox species, and why?

lovotibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
Species
Mouse only (beta-thalassemic and wild-type C57BL/6 transplant models; immunodeficient mice for human cells)
“The following toxicology studies were conducted to evaluate the safety of human HSCs or mBMCs transduced with BB305 LVV following administration in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 16Source ↗
Why that species
Beta-thalassemic (Hbbth1/th1) mouse disease model allowed pharmacology and toxicity assessment of transduced syngeneic marrow
“To evaluate the pharmacologic and toxicologic effects of mBMCs transduced with BB305 LVV or mBMCs transduced with HPV569 LVV following IV administration in β-thalassemic mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 17Source ↗
Surrogate molecule
Yes: murine bone marrow cells transduced with clinical BB305 vector (homologous cell product); human CD34+ in immunodeficient mice
“Test Articles • mBMCs transduced with BB305 LVV (Lot No. • mBMCs transduced with HPV569 LVV (Lot No. Control Article mBMCs; mock-transduced”
✓ VerifiedFDA pharmacology/toxicology review, p. 17Source ↗
Species: general tox
Mouse only (β-thalassemic and wild-type C57BL/6 primary/secondary transplant studies)
“In vivo studies were also conducted to assess the activity and safety of mBMCs transduced with BB305 following primary and secondary transplantation in β-thalassemic and wild-type C57BL/6 mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Species: DART
Not conducted (no adverse findings in mouse reproductive tissues)
“Per the applicant, developmental and reproductive toxicology studies were not conducted because there were no adverse findings in the male and female reproductive tissues of mice administered mBMCs transduced with BB305 LVV”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Species: carcinogenicity
Not conducted (acceptable based on product type)
“No traditional carcinogenicity studies were conducted with lovo-cel which is acceptable based on the product type.”
✓ VerifiedFDA pharmacology/toxicology review, p. 26Source ↗
Surrogate used in
Yes: murine bone marrow cells as surrogate cell product; SCD transgenic mouse POC used a related βA-T87Q vector
“In vivo POC studies were also conducted using transgenic mouse models of SCD, where murine bone marrow cells (mBMCs) were transduced with the βA-T87Q LVV, a related vector encoding the same transgene, and showed expression of βA-T87Q and correction of the sickling phenotype through 3 months post-transplantation.”
✓ VerifiedFDA summary basis for approval, p. 11Source ↗

Same question, other gene therapies

Adstiladrin

nadofaragene firadenovec · IFN-alpha2b (adenovirus, intravesical)
Cynomolgus monkey for rAd-IFN/Syn3 GLP tox; rat and monkey for excipient Syn3

Beqvez

fidanacogene elaparvovec · Factor IX
Cynomolgus monkey and mouse (tox); hemophilia B dog and mouse (pharmacology); rabbit (shedding)

Casgevy

exagamglogene autotemcel · BCL11A enhancer (CRISPR-Cas9, ex vivo HSC)
Mouse only (irradiated NSG immunodeficient xenotransplant mice)

Elevidys

delandistrogene moxeparvovec · Micro-dystrophin
Mouse only (wild-type C57BL/6J and mdx disease model); NHP only in non-GLP supporting studies

Fayuvi

rebisufligene etisparvovec · SGSH (AAV9)
Wild-type C57BL/6 mice only (6-month and 3-month GLP studies)

Genglycos

pariglasgene brecaparvovec · G6PC (AAV8)
Mouse (adult and juvenile C57BL/6N) and juvenile cynomolgus monkey; GLP single-dose studies

Glybera

alipogene tiparvovec · LPL (AAV1)
Wild-type mouse only for GLP tox; PD in LPL-/- mice and LPL-deficient cats; biodistribution in cats, mice, rabbits

Hemgenix

etranacogene dezaparvovec · Factor IX
Mouse and cynomolgus monkey

Imlygic

talimogene laherparepvec · GM-CSF (oncolytic HSV-1)
Mouse (BALB/c) for GLP tox; single-dose studies also in rats and dogs; no permissive/relevant species for human GM-CSF

Itvisma

onasemnogene abeparvovec (intrathecal) · SMN1 (AAV9, intrathecal)
Cynomolgus monkey (pivotal IT tox); FVB mice for ICV safety and fertility/EFD; SMA piglet and SMN-delta7 mouse pharmacology

Kebilidi

eladocagene exuparvovec · AADC
Rat (pivotal GLP); cynomolgus monkey for biodistribution/excipient studies

Kresladi

marnetegragene autotemcel · ITGB2 (LVV, ex vivo HSC)
Mouse only (CD18HYP/CD18KO disease models, recipient mice, NSG mice); no large-animal tox

Lenmeldy

atidarsagene autotemcel · ARSA (LVV, ex vivo HSC)
Mouse (As2-/- MLD model, murine ARSA-LV HSPCs) for pivotal GLP; immunodeficient mice for human-cell biodistribution

Luxturna

voretigene neparvovec · RPE65
Dog (normal-sighted and RPE65-mutant Briard) and non-human primate

Otarmeni

lunsotogene parvec · OTOF (AAV, intracochlear)
Mouse (Otof-Q828X hom disease model) and cynomolgus monkey

Papzimeos

zopapogene imadenovec · HPV6/11 antigens (gorilla adenovirus)
Mouse only (wild-type C57BL/6); no NHP studies

Roctavian

valoctocogene roxaparvovec · Factor VIII
Mouse (CD1, Rag2-/-, hemophilia A models) and cynomolgus/rhesus monkey; all males

Skysona

elivaldogene autotemcel · ABCD1 (LVV, ex vivo HSC)
Mouse only: myeloablated immunodeficient NSG/NSGS mice given human CD34+ HSCs

Strimvelis

autologous CD34+ cells transduced with ADA (no INN) · ADA (gamma-retroviral, ex vivo HSC)
NSG immunodeficient mouse only (xenograft of transduced human CD34+ cells)

Tudriqev

vusolimogene oderparepvec · GALV-GP + GM-CSF (oncolytic HSV-1)
Tumor-bearing immunocompetent mice (TUDRIQEV, mRP1) and healthy rats (murine surrogate mRP1)

Vyjuvek

beremagene geperpavec · COL7A1 (HSV-1, topical)
Mouse only (BALB/c) for GLP tox; single species

Waskyra

etuvetidigene autotemcel · WAS (LVV, ex vivo HSC)
Mouse only: WAS knockout (C57BL/6 and SV129) mice with murine surrogate cells; Rag2-/-IL2rg-/- mice for human-cell fate

Zevaskyn

prademagene zamikeracel · COL7A1 (RV-modified keratinocyte sheets)
Mouse only (immunodeficient mice with implanted human keratinocyte products); no relevant large-animal species

Zolgensma

onasemnogene abeparvovec · SMN1
Mouse only for pivotal GLP tox (neonatal FVB); NHP only in non-GLP studies (later 6-month juvenile NHP study in label)

Zynteglo

betibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
Mouse only (beta-thalassaemic Hbbth1/th1 and wild-type C57BL/6; immunodeficient NSG for human HSC); murine surrogate product

Summary across all 26 gene therapies →